TUBERCULOSIS

Rapid and specific labeling of single live Mycobacterium tuberculosis with a dual-targeting fluorogenic probe

Yunfeng Cheng1*, Jinghang Xie1*, Kyung-Hyun Lee1,2, Rajiv L. Gaur3,4,5, Aiguo Song1, Tingting Dai1, Hongjun Ren6, Jiannan Wu7,8, Zhaogang Sun7,8, Niaz Banaei3,4,5, Demir Akin9, Jianghong Rao1†

Tuberculosis (TB) remains a public health crisis and a leading cause of infection-related death globally. Although in high demand, imaging technologies that enable rapid, specific, and nongenetic labeling of live Mycobacterium tuberculosis (Mtb) remain underdeveloped. We report a dual-targeting strategy to develop a small molecular probe (CDG-DNB3) that can fluorescently label single bacilli within 1 hour. CDG-DNB3 fluoresces upon activation of the β-lactamase BlaC, a hydrolase naturally expressed in Mtb, and the fluorescent product is retained through covalent modification of the Mtb essential enzyme decaprenylphosphoryl-β-α-ribose 2'-epimerase (DprE1). This dual-targeting probe not only discriminates live from dead Bacillus Calmette-Guérin (BCG) but also shows specificity for Mtb over other bacterial species including 43 nontuberculosis mycobacteria (NTM). In addition, CDG-DNB3 can image BCG phagocytosis in real time, as well as Mtb in patients’ sputum. Together with a low-cost, self-driven microfluidic chip, we have achieved rapid labeling and automated quantification of live BCG. This labeling approach should find many potential applications for research toward TB pathogenesis, treatment efficacy assessment, and diagnosis.

INTRODUCTION

Tuberculosis (TB), an infectious disease caused by the slow-growing pathogen Mycobacterium tuberculosis (Mtb), kills an estimated 2 million people per year according to World Health Organization (1–3). Emergence of multidrug resistance with synergistic interaction with HIV/AIDS pandemic exacerbated this problem and reactivated a global concerted effort on TB research (4, 5). Microbial cell culture is considered as the gold standard for TB diagnosis; however, it is time-consuming—usually taking 1 to 2 months to complete because of the extremely slow growth rate of Mtb. Although nucleic acid amplification technology for detecting the DNA material from Mtb has advanced (6–8), imaging technologies that allow rapid and specific labeling of live Mtb have seen little progress (9). Since the introduction of fluorochrome staining by Hagemann in 1937, auramine O has been widely adopted for Mtb fluorescent microscopic examination. Auramine O interacts with the mycolic acids within the cell wall of acid-fast microorganisms like mycobacteria, but is not specific to Mtb and cannot discriminate viable from dead cells. Auramine O sensitivity is also undesirable and varies because of tedious staining, decolorizing, and counterstaining procedures (10, 11). Replacing this century-old technology has proven not a trivial effort: Molecular probes for live Mtb labeling have been developed to target the capsular components such as esterases (12, 13), the d-Ala-d-Ala motif of peptidoglycan (14, 15), trehalose mycolyltransesterases (16–19), and sulfatases (20), yet none has been shown to be specific for labeling Mtb. Esterases, the d-Ala-d-Ala motif, and sulfatases exist not only in mycobacteria but also in many other bacterial strains. Trehalose mycolyltransesterases are expressed in Actinobacteria phylum including mycobacteria; thus, trehalose-based probes do not have Mtb specificity either (19).

Recently, electron-deficient nitroaromatic compounds have been discovered as a new class of potent anti-TB agents (21–23) that target decaprenylphosphoryl-β-α-ribose 2’-epimerase (DprE1), a periplasmic enzyme highly conserved among actinobacteria and required for the synthesis of the cell wall arabinans. Specifically, DprE1 reduces one nitro group of these compounds to a nitroso derivative and covalently modifies this nitroso to form a stable semi-mercaptal complex using the cysteine residue in the active site. This mechanism presents a possibility to design a fluorescent probe to image Mtb at the single-cell level through DprE1-mediated signal retention.

Mtb is intrinsically resistant to nearly all β-lactam antibiotics, largely because of the production of an ambler class A β-lactamase named BlaC that is highly conserved through clinical isolates (24, 25). By engineering the core structure of a β-lactam cephalosporin, we recently developed a fluorogenic probe that is specific to BlaC (26–28), but because of signal diffusion, it cannot be used for single-cell Mtb labeling. Here, we report a fluorogenic probe that targets both BlaC and DprE1 to achieve specific labeling of single live Mtb in less than 1 hour.

RESULTS

Design of dual-targeting fluorogenic probes

Our dual-targeting fluorogenic probes (CDG-DNBs) contain three functional units: a BlaC-sensing unit, a caged fluorescent reporter, and a DprE1-binding unit for signal trapping (Fig. 1A). We reasoned that CDG-DNBs would pass the Mtb cell wall (mycolate arabinogalactan layer) through porins, because the uptake of cephalosporin
The binding affinity upon covalent modification by these analogs was first studied in vitro with purified recombinant *Mycobacterium smegmatis* DprE1 (DprE1SM) (fig. S8). As shown in Fig. 2B, fluorophore-dinitrobenzene (DNB) analogs labeled DprE1SM with different efficiency: Mono-nitro probes (Rd-MNB and FI-MNB) showed negligible fluorescence compared to di-nitro analogs, and TG-DNB2 exhibited the highest DprE1SM labeling efficiency. This result is consistent with the literature indicating that an electron-withdrawing substituent in the meta position is required for DprE1SM binding (23). TG-DNB2 is favored because it closely resembles the optimal DprE1-binding candidate DNB1 (Fig. 2A) (22). The covalent labeling of DprE1SM by TG-DNB2 was further validated with varying conditions. The fluorescent complex TG-DNB2-DprE1SM was observed only when DprE1SM, TG-DNB2, and the lysate were present simultaneously (Fig. 2C, lane 4). Conditions missing the lysate [thus the substrate decaprenylphosphoryl-β-D-ribofuranose (DPR) and the cofactor flavin adenine dinucleotide (FAD); lane 1], DprE1SM (lane 2), or the DNB function group (lane 3) failed to produce the fluorescent complex. As expected,
functional DprE1_{SM} protein was required: There was no labeling when it was denatured by heat (lane 5) or 7 M urea/dithiothreitol (DTT) reduction (lane 6). Preincubation with DNB1 also blocked the labeling of DprE1_{SM} by TG-DNB2 (lane 7). Collectively, these data support that labeling of DprE1_{SM} by TG-DNB2 proceeded through the reduction-covalent modification mechanism.

We further tested the fluorescence labeling and retention of TG-DNBs in different bacteria strains including \textit{M. smegmatis}, \textit{Mycobacterium abscessus}, \textit{Escherichia coli}, \textit{Streptococcus pneumoniae}, \textit{Staphylococcus aureus}, and \textit{Corynebacteria diphtheriae}. \textit{M. smegmatis} is one of the most commonly used fast-growing mycobacteria in the laboratory. \textit{M. abscessus} is a prevalent human-infecting nontuberculosis mycobacterium (NTM) (31). Unlike \textit{M. smegmatis} containing Cys^{394} in the DprE1_{SM} (MSMEG_6382) active pocket (Cys^{387} in Mtb), the active cysteine residue (Mabs_{19977}) in \textit{M. abscessus} DprE1 is replaced by an alanine (Ala^{395}; fig. S9); thus, \textit{M. abscessus} is naturally resistant to TG-DNB modification. \textit{C. diphtheriae}, the pathogenic bacterium also belonging to actinobacteria, carries a similar capsular structure to mycobacterium and the DprE1 homolog DIP1062 (72% identical/82% similar to DprE1_{SM}) that contains a conserved cysteine residue (Cys^{413}) in its active site (fig. S9) (32). \textit{S. pneumoniae} and \textit{S. aureus} as human respiratory pathogens were included as control strains to test for specificity (33, 34). As shown in Fig. 2D, TG-DNB1 and TG-DNB2 both exhibited distinct fluorescence labeling in \textit{M. smegmatis} and \textit{C. diphtheriae} but not in other strains, whereas none of the phosphate-buffered saline (PBS)– or TG-treated bacteria showed any fluorescence retention (fig. S10).
a polarized distribution of DprE1 in *M. smegmatis* (Fig. 2E). The treated bacteria were further analyzed by flow cytometry. Similar to the results of fluorescence microscopy, TG-DNB2 gave a 150-fold fluorescence enhancement relative to the PBS-treated *M. smegmatis*, and TG-DNB1 showed a 50-fold fluorescence enhancement (Fig. 2F). One-hour incubation with 10 μM TG-DNB2 at room temperature could reach the maximal fluorescence in *M. smegmatis* without affecting its growth curve (figs. S11 and S12). An abolishment of the fluorescence by preincubating *M. smegmatis* with DNB1 before TG-DNB2 treatment further validated the specific retention through DprE1 covalent modification (fig. S13). Together, these data established the use of DprE1 as the target for trapping fluorophores through a covalent adduct formation.

**Evaluation of dual-targeting probes CDG-DNB1/2 for labeling mycobacteria**

Because mycobacteria generally express β-lactamases (BlaC in Mtb, BlaS in *M. smegmatis*, and Bla*mb* in *M. abscessus*), we sought to convert TG-DNB1 and TG-DNB2 into fluorogenic probes that could fluoresce only upon β-lactamase activation. Such dual-targeting strategy should further enhance selectivity and also lower the background from nonspecific interactions. On the basis of TG-DNB1 and TG-DNB2, we designed, synthesized, and tested two dual-targeting probes: CDG-DNB1 and CDG-DNB2 (Fig. 3A, see synthesis in figs. S5 and S6). Intense fluorescence was observed in *M. smegmatis* expressing both DprE1 and BlaS after incubating with CDG-DNB1 (fig. S14A) and CDG-DNB2 (Fig. 3B). A control probe (CDG−1) without DprE1 targeting showed no fluorescence retention (fig. S14A). Flow cytometry analysis revealed that CDG-DNB2−treated *M. smegmatis* could generate an 80-fold enhancement in fluorescence intensity (Fig. 3C) and about 30-fold for CDG-DNB1, owing to lower DprE1 mediated labeling efficiency by its uncaged product TG-DNB1 (fig. S14, B and D). Control strains expressing β-lactamase but not DprE1 (β-lactamase−/DprE1−) included TEM−1 β-lactamase (TEM−1 Bla) transformed *E. coli* (figs. S14 and 15A), *S. pneumoniae*, *S. aureus*, and *M. abscessus* (fig. S14). Although they could hydrolyze CDG-DNB2 to uncape the fluorophore, no fluorescenly labeled cells were observed because of the lack of or mutated DprE1 (Fig. 3B). *C. diptheriae* (β-lactamase−/DprE1−), on the other hand, was unable to release the caged fluorophore. An inhibition study with a β-lactamase inhibitor (clavulanic acid) and DprE1 inhibitor (DNB1) decreased the fluorescent signals by 60% in *M. smegmatis*, offering further evidence supporting this dual-targeting mechanism (Fig. 3D). *M. smegmatis* expresses a major β-lactamase called BlaS and a minor β-lactamase called BlaE. BlaE is a type 1 β-lactamase and is not as sensitive to the clavulanic acid inhibition (24), which may explain why some β-lactamase activity remained in *M. smegmatis* in the presence of clavulanic acid.

Next, we tested CDG-DNB2 in freshly cultured *Mycobacterium bovis* Bacillus Calmette-Guérin (BCG) and Mtb H37Rv, both of which expressed BlaC and DprE1. After 1-hour incubation at room temperature, both bacilli exhibited sharp green fluorescence, but not in CDG−1− or PBS-treated groups (Fig. 3E and fig. S16). Further quantification by flow cytometry showed an 80-fold increase in the fluorescence intensity with CDG-DNB2−treated BCG and 52-fold increase in H37Rv (fig. S16). In a BlaC knockout (KO) H37Rv strain stained with CDG-DNB2, the fluorescence labeling was compromised by 55% but could be restored by BlaC transformation (fig. S17). We note that this BlaC KO strain was reported to have additional β-lactamase activity (24), which may contribute to the remaining signal.

To demonstrate rapid labeling of live BCG, we tested a nonwash CDG-DNB2 staining protocol for real-time imaging. A time-dependent enhancement of green fluorescence was observed in continuous imaging at an interval of 2.5 min for 65 min (movies S1 and S2). Prominent green fluorescence in BCG was observed as early as 15 min. This rapid labeling indicated fast penetration of CDG-DNB2 into BCG (Fig. 3F), which prompted investigation into whether CDG-DNB2 could also label single Mtb in patient sputum. Four sputum specimens (two GeneXpert/smear−positive and two negative) were collected, processed and neutralized, and then stored at 4°C for 2 days before incubation in 10 μM CDG-DNB2/PBS solution at room temperature for 1 hour. Sediments by centrifugation were washed three times and then resuspended in acidic buffer for confocal imaging. Single rod-shaped bacilli with emerald green fluorescence were observed in both TB−positive specimens (fig. S18).

**Rapid and specific labeling of live Mtb by CDG-DNB3**

To enhance the specificity of dual-targeting probes for Mtb over other mycobacteria, we introduced a methoxy substitution to the lactam ring at 7−position on CDG-DNB2 (26, 27) to produce CDG-DNB3 (Fig. 4A and fig. S7). The quantum yields of CDG-DNB3 (φ = 0.01) and its fluorogenic product TG-DNB2 (φ = 0.77) were measured in 0.1 M phosphate buffer using fluorescein as a reference standard (φ|| = 0.85; excitation, 490 nm) (35). When incubated with CDG-DNB3, TEM−1 Bla showed negligible activity, whereas BlaC activated fluorescence at a 200-fold lower concentration. CDG-DNB2, in contrast, could be activated by both β-lactamases (fig. S19). CDG-DNB3 and its product TG-DNB2, with or without clavulanic acid or DNB1, showed little change in their fluorescence (fig. S20), which confirmed that observed fluorescence activation with CDG-DNB3 was from the BlaC enzymatic activity. No fluorescence increase was observed when CDG-DNB3 was treated with DprE1, indicating that DprE1 most likely plays the role of a signal-trapping unit and, alone, does not cause the fluorescence increase in CDG-DNB3 (fig. S20). CDG-DNB3 was also characterized in bacteria. The findings were congruent with the enzymatic study—that CDG-DNB3 selectively stained BCG but not *M. smegmatis*, TEM−1 Bla, or BlaC transformed *E. coli* (Fig. 4B and fig. S21).

Current staining probes, including auramine O and the trehalose probe, cannot differentiate Mtb from NTMs. To evaluate the selectivity of CDG-DNB3 for Mtb over other mycobacteria, we introduced a methoxy substitution to the lactam ring at 7−position on CDG-DNB2 (26, 27) to produce CDG-DNB3 (Fig. 4A and fig. S7). The quantum yields of CDG-DNB3 (φ = 0.01) and its fluorogenic product TG-DNB2 (φ = 0.77) were measured in 0.1 M phosphate buffer using fluorescein as a reference standard (φ|| = 0.85; excitation, 490 nm) (35). When incubated with CDG-DNB3, TEM−1 Bla showed negligible activity, whereas BlaC activated fluorescence at a 200-fold lower concentration. CDG-DNB2, in contrast, could be activated by both β-lactamases (fig. S19). CDG-DNB3 and its product TG-DNB2, with or without clavulanic acid or DNB1, showed little change in their fluorescence (fig. S20), which confirmed that observed fluorescence activation with CDG-DNB3 was from the BlaC enzymatic activity. No fluorescence increase was observed when CDG-DNB3 was treated with DprE1, indicating that DprE1 most likely plays the role of a signal-trapping unit and, alone, does not cause the fluorescence increase in CDG-DNB3 (fig. S20). CDG-DNB3 was also characterized in bacteria. The findings were congruent with the enzymatic study—that CDG-DNB3 selectively stained BCG but not *M. smegmatis*, TEM−1 Bla, or BlaC transformed *E. coli* (Fig. 4B and fig. S21).
auramine O, propidium iodide (PI), and CDG-DNB3 for comparison (Fig. 4C and fig. S22). The red fluorescence observed in PI-stained BCG and *E. coli* indicated the loss of membrane integrity after autoclave. Carbol fuchsin and auramine O could discriminate between BCG and *E. coli*; however, they were unable to differentiate live from dead *M. tb*. CDG-DNB3–labeled BCG showed an identical growth curve to unlabeled BCG, unlike auramine O staining with phenol that considerably compromised the viability of stained BCG (fig. S12B). We further examined whether CDG-DNB3 could fluorescently label BCG for macrophage infection. BCG was preincubated with CDG-DNB3 before macrophage infection (two to three bacteria per macrophage). As shown in Fig. 4D, green fluorescence of internalized individual bacilli in macrophages was observed after 4 hours of infection (movie S3). Although *M. tb* may be genetically labeled with fluorescent proteins for real-time imaging of phagocytosis (38), the CDG-DNB3 method can be simply applied to wild-type (WT) *M. tb* and clinical isolates without any genetic manipulation that may pose unexpected effects such as changes in virulence.

Last, we applied CDG-DNB3 for staining of sputum. Single rod-shaped and green fluorescent bacilli were observed in all three clinically confirmed positive processed sputum specimens (fig. S23). One of the TB patient’s sputum that labeled with CDG-DNB3 (patient 5) was GeneXpert-positive but auramine O–negative, implicating higher sensitivity of CDG-DNB3 than auramine O.

**Automated counting of the number of stained BCG with a microfluidic chip**

Clinically, after smear staining with auramine O, slides are manually examined under a fluorescence microscope to count the number of stained *M. tb*, which is a tedious and labor-intensive process. To evaluate whether CDG-DNB3 labeling could provide a solution for rapid counting of *M. tb* in combination with microfluidic technology,

---

**Fig. 3. Characterization of the dual-targeting probe CDG-DNB2.** (A) Structure of CDG-DNB2. (B) Overlaid confocal images (bright-field and green fluorescence; 63×/oil; excitation, 490 nm; emission, 520 nm) of freshly cultured *E. coli* expressing TEM-1 β-lactamase, *S. pneumoniae*, *S. aureus*, *M. abscessus*, *C. diphtheriae*, and *M. smegmatis* stained with 10 μM CDG-DNB2 in PBS at room temperature for 1 hour. (C) Histogram of normalized fluorescence from fluorescence-activated flow cytometry data with bacteria in (B). (D) Normalized fluorescence from *M. smegmatis* treated with CDG-DNB2 with and without β-lactamase inhibitor clavulanic acid (10 mM) and DNB1 (50 μM), analyzed by flow cytometry. *M. smegmatis* treated with CDG-DNB2 exhibited an average 90-fold increase of MFI over PBS, which was arbitrarily set to 1 to normalize the other groups with inhibitors. (E) Overlaid confocal images of freshly cultured BCG and H37Rv *M. tb* stained with CDG-DNB2. (F) Real-time confocal imaging of CDG-DNB2–treated BCG aggregates showing a time-dependent enhancement of green fluorescence.
Fig. 4. Specific labeling of live Mtb by CDG-DNB3. (A) Structure of CDG-DNB3. (B) Histogram of fluorescence-activated flow cytometry analysis with freshly cultured E. coli (TOP10) expressing TEM-1 β-lactamase, E. coli (TOP10) expressing BlaC, M. smegmatis, and BCG stained with 10 μM CDG-DNB2 or CDG-DNB3 in PBS at room temperature for 1 hour: 1: CDG-DNB2–treated group; 2: CDG-DNB3–treated group. (C) Microscopic imaging of freshly cultured (top row) and 121°C autoclaved (bottom row) BCG stained by Ziehl-Neelsen reagents, auramine O (green; excitation, 490 nm; emission, 520 nm), PI (red; excitation, 535 nm; emission, 617 nm), or CDG-DNB3 (10 μM, 1 hour). (D) Infection of macrophages by CDG-DNB3–labeled individual BCG bacilli: (I) bright-field image of BCG-infected macrophages (bacilli are indicated by arrows); (II) overlay of bright-field and fluorescence images showing the localization of CDG-DNB3–stained bacilli (green; excitation, 490 nm; emission, 520 nm); (III) overlay of fluorescence images showing the bacilli (green) and 4',6-diamidino-2-phenylindole (DAPI)–stained nucleus (blue; excitation, 358 nm; emission, 461 nm); (IV) overlay of fluorescence image showing the bacilli, nucleus, and the macrophage plasma membrane (magenta; excitation, 649 nm; emission, 666 nm); (V to VII) orthogonal views (XY, XZ, and YZ) of the bacilli indicated by arrows in (IV). ImageJ was used for image processing and stack projection.
we designed a quantification strategy using a self-driven microfluidic chip (Fig. 5 and fig. S24). When the CDG-DNB3–labeled BCG was loaded on the chip, the fluid was dragged to flow along the channel by the capillary pump with no need for any extra pumping device (“self-driven” feature) (Fig. 5, A and B). Four parallel channels across the detection window allowed for rapid detection and automatic counting of fluorescent BCG using a publicly available software (Fig. 5C). In an exemplary test run (movie S4), a total of 306 bacteria were detected in 2.42 s with a flow rate of 2.5 nl/s, corresponding to a concentration of $1.6 \times 10^7$ colony-forming units (CFU)/ml in a volume of 6 nl, consistent with calculation by measuring optical density of the BCG solution [optical density at 600 nm (OD$_{600}$)].

**DISCUSSION**

Noninvasive fluorescence imaging technologies for bacteria have revealed greater insights into the small organisms (39), from membrane and intracellular structures to specific protein localization and trafficking dynamics. A common approach for fluorescent labeling of live bacteria uses the genetic fusion of a fluorescent protein or epitope tag to a protein of interest. In comparison, small-molecule fluorescent probes can enable visualization of many nonprotein targets, but the small size and thick cell envelope of bacteria present big challenges for probe development. In particular, Mtb is known for having a nearly impenetrable cell wall. Here, we report a powerful dual-targeting approach in designing small-molecule probes for rapid and specific labeling of live Mtb.

We propose the use of two enzymes in the cell wall and membrane layers of Mtb as imaging markers: BlaC, an ambl class $\beta$-lactamase highly conserved through clinical isolates, and DprE1, a periplasmic enzyme required for the biosynthesis of the cell wall arabinos and highly conserved among actinobacteria. BlaC has been explored for Mtb detection, and preliminary testing with spum samples showed promises for TB diagnosis (27), but targeting BlaC alone does not allow for single Mtb labeling (fig. S14A). The combination of BlaC and DprE1 in a dual-targeting probe offers considerable advantages. As our results demonstrate, this strategy is specific for Mtb over other clinically prevalent strains, including 43 of 45 closely related NTMs we tested. Fluorophore and lactam conjugates have been reported to target penicillin-binding proteins (PBPs) for bacterial labeling (40, 41). However, it is unknown whether PBPs can serve as the target for specific labeling of Mtb. It is unlikely that our probes are processed by PBPs due to the modifications on the lactam; those bacteria without $\beta$-lactamase cannot be fluorescently labeled with our probes even with the expression of DprE1 (for example, *C. diphtheriae*).

Another important feature provided by the dual-targeting approach is the ability to label single-cell live Mtb. Live BCG was successfully labeled, without any genetic modification, to image phagocytosis by macrophages. It is likely that our probe could similarly rapidly and specifically label live Mtb in clinical samples to detect and isolate labeled mycobacteria using cell sorting for further analysis, such as culturing or drug sensitivity assays. We also designed a microfluidic device and workflow to automate quantification of individual fluorescently labeled BCG; it took about 20 min for a total volume of 10 nl of stained bacteria mixture to flow through the detection window. In principle, this method could lead to a detectable concentration of 100 CFU/ml, assuming one copy of BCG in the loading mixture. Further optimization, such as increasing the number of channels on the chip to load larger sample volumes, may allow an even more rapid detection and a lower detection limit. The materials and fabrication costs of each off-the-shelf chip are estimated to be $0.65 in an academic research setting but may be reduced by 5 to 10 times in a large-scale manufacturing facility via the use of thermoplastic polymer chips and injection molding. The combination of rapid, specific CDG-DNB3 labeling and the low-cost microfluidic chip provides a simple and cost-effective solution to automated counting of live Mtb in samples.

In summary, this study reports a dual-targeting approach using the expression of BlaC and DprE1 in Mtb to develop CDG-DNB3, a fluorogenic probe that enables rapid, specific fluorescent labeling and quantification of single live Mtb. A series of biochemical assays and microscopic imaging experiments have successfully validated the BlaC/DprE1 dual-targeting mechanism and demonstrated that CDG-DNB3 can differentiate Mtb from other clinically prevalent strains, distinguish live from dead BCG, and image BCG infection in macrophages. Finally, a low-cost, self-driven microfluidic chip was successfully developed to rapidly count the number of CDG-DNB3–stained BCG. This rapid, noninvasive, specific labeling and counting of live Mtb positions CDG-DNB3 as a potentially powerful probe for pathogenesis study, drug and vaccine screening, drug susceptibility testing, treatment efficacy assessment, and diagnosis of TB.
MATERIALS AND METHODS

Study design

The goal of this study was to develop a rapid and specific fluorogenic probe for the detection of Mtb in both laboratorial and clinical settings. The probe CDG-DNB3 carries a caged fluorophore that fluoresces only upon enzymatic activation by Mtb-specific BlaC. The fluorescence product generated by BlaC cleavage was retained through a covalent modification at the cysteine residue 387 of DprE1, an essential enzyme for Mtb cell wall biosynthesis. To discover the optimal structure to label DprE1, we synthesized a series through a covalent modification at the cysteine residue 387 of DprE1. The probe CDG-DNB3 carries a caged fluorophore that fluoresces only upon enzymatic activation by Mtb-specific BlaC. The fluorogenic product generated by BlaC cleavage was retained through a covalent modification at the cysteine residue 387 of DprE1, an essential enzyme for Mtb cell wall biosynthesis. The probe CDG-DNB3 was evaluated for differentiating M. smegmatis from bacterial and corynebacterial strains, and other clinically prevalent but DprE1− or cysteine-mutated bacterial and mycobacterial strains. Next, the DprE1-targeting unit was introduced into the BlaC-targeting cephalosporin derivative to generate CDG-DNB3, selective for Mtb over other non-Mtb mycobacterial strains (NTMs). As an enzyme-dependent probe, CDG-DNB3 was evaluated for differentiating NTMs and viability of BCG for imaging phagocytosis in real time. The utility of the dual-targeting probes was also tested in two small groups of TB patient sputum. In the United States, fresh patient sputum specimens were collected by the Clinical Microbiology Laboratory at Stanford University Medical Center. Experiments in this work used discarded sputum samples, and no institutional review board approval was required. In China, ethics approval for the use of the six patient samples was provided by the Ethics Committee of the Beijing Chest Hospital affiliated to the Capital Medical University. The experiments with biohazard materials were designed and performed adhering to the biosafety guidelines at Stanford University and Beijing Chest Hospital. Finally, a portable microfluidic device was designed, and a workflow was applied for automated counting of CDG-DNB3-labeled BCG.

Expression and purification of M. smegmatis DprE1

The general expression and purification procedures were described previously (42). In brief, a single colony of BL21(DE3) containing the PET-SUMO-DprE1 plasmid was inoculated into 100 ml of lysogeny broth (LB) with kanamycin (50 μg/ml), followed by incubation at 37°C and 250 rpm overnight. The overnight culture was added into 500 ml of fresh LB with kanamycin (50 μg/ml) and 1 mM isopropyl-β-D-1-thiogalactopyranoside. After incubation for up to 6 hours at 37°C and 250 rpm, bacteria were harvested and pellet was frozen at −80°C before resuspension in 22.5 ml of lysis buffer [25 mM Hepes (pH 7.4), 300 mM KCl, and 10% glycerol]. Lysozyme (2.5 ml of 7.5 mg/ml) was added to the bacteria lysate before two rounds of metal affinity purification using TALON metal affinity resin. The affinity-purified DprE1sm fraction was eluted using lysis buffer containing up to 500 mM imidazole. DprE1sm was then dialyzed into Hepes buffer [25 mM Hepes and 10% glycerol (pH 7.4)] and stored at −80°C. Tag cleavage was achieved by overnight incubation with SUMO protease (Thermo Fisher Scientific), followed by a third-round affinity purification to remove both His6-SUMO tag and SUMO protease.

Sample preparation for SDS-PAGE analysis

Typically, aliquots of the purified protein DprE1sm [50 μM in 50 mM Hepes/10% glycerol (pH 7.5)] were incubated with 10 μM FL, FL-DNB1/2, FL-MNB, Rd-Boc, Rd-DNB, Rd-MNB, or TG-DNB1/2 [from 1 mM stock in dimethyl sulfoxide (DMSO)] and 100-μg whole lystate of M. smegmatis containing phenylmethylsulfonyl fluoride (1 mM) in a final volume of 30 μl at 37°C for 1 hour. The whole lystate of freshly cultured M. smegmatis provided the natural substrate DPR and the cofactor FAD that are essential for the generation of DNB-DprE1 covalent products. As negative controls, (i) DprE1sm was preheated for 1 hour at 90°C to denature the protein. (ii) The sample buffer was adjusted to 7 M urea and 20 mM DTT after incubation. These samples were further incubated for 1 hour at 37°C. (iii) DprE1sm was incubated with 50 μM DNB1 for 1 hour before addition of TG-DNB2. Samples were treated with 4× LDS loading buffer (Life Technologies) without heating and analyzed by SDS–polyacrylamide gel electrophoresis (PAGE) (NuPAGE, Life Technologies). The analysis was performed in duplicate.

Bacteria growth and staining

BCG [American Type Culture Collection (ATCC) 35734], Mtb H37Rv (ATCC 25618), M. smegmatis MC2−155 (ATCC 700084), S. pneumoniae (ATCC 49619), S. aureus (ATCC 25923), M. abscessus (ATCC 19977), and C. diphtheriae (ATCC 13812) were purchased from ATCC. All other NTMs were purchased from ATCC or other specified DSMZ (Deutsche Sammlung von Mikroorganismen und Zellkulturen).

In general, M. smegmatis, BCG, and H37Rv were cultured in Middlebrook 7H9 broth supplemented with ADC enrichment and 0.1% Tween 80. E. coli (TOP10) was grown in LB medium. S. pneumoniae was grown on tryptic soy agar plates supplemented with defibri- nated sheep blood at 5% CO2 and 37°C. S. aureus, M. abscessus, and C. diphtheriae were grown on tryptic soy agar plates supplemented with defibri- nated sheep blood at 37°C. The unit CFU/ml was determined by measuring the optical absorbance at 600 nm (OD600).

For growth curve, M. smegmatis was pretreated with PBS, 10 μM TG-DNB2, and 10 μM CDG-DNB2 for 1 hour or 2% NaOH for 20 min at room temperature. Culture of pretreated M. smegmatis was started at OD600 = 0.1 in 7H9 medium for all groups at 37°C and 220 rpm. OD600 of each sample was measured every 2 hours over 14 hours. Similarly, BCG was pretreated with PBS and 10 μM CDG- DNB3 at room temperature for 1 hour or auramine O (AlphaTec). Culture of pretreated BCG was started at OD600 = 0.4 to 0.5 in 7H9 medium for all conditions at 37°C and 80 rpm. OD600 of each sample was measured daily for 10 days. Experiments were repeated three times.

For TG, TG-DNB1/2, and CDG-DNB2/3 analog staining in the laboratory, 500 μM probes in pure DMSO were frozen at −80°C as stock solutions. Working solution (20 μM) was prepared freshly by diluting stock solution in PBS. Staining was done by mixing bacteria in PBS resuspension and 20 μM working solution in a 1:1 volume ratio, left in room temperature for 1 hour, then centrifuged at 3000 g, and washed three times stringently with PBS. A light safe tube or foil wrap was used to prevent photobleaching during incubation. Bacteria were fixed in 10% formalin for 30 min before centrifugation and resuspension in saline for flow cytometry analysis. For CDG-DNB3 staining to differentiate live and autoclaved BCG or E. coli, a wash step with alcohol/water was performed immediately after staining, and two additional PBS washes were performed before formalin fixing.

For Zielh-Neelsen staining, briefly, freshly cultured or 121°C/20-min autoclaved BCG and E. coli were smeared and fixed by gentle heat on glass slides and then stained with carbol fuchsin for 3 min. The smears were decolorized with acidic alcohol and then rinsed with sterile water, followed by counterstaining with methylene blue for 1 to 2 min, rinsing, and drying for immediate microscope imaging.

For auramine O staining, briefly, freshly cultured or 121°C/20-min autoclaved BCG and E. coli were smeared and fixed by methanol on glass slides and then stained with auramine O for 15 min. Smears were rinsed with sterile water and decolorized by acidic alcohol for 3 min. The smears were rinsed again with sterile water, counterstained by potassium permanganate for 4 min, and finally rinsed and dried for immediate microscope imaging.

For PI staining, briefly, freshly cultured or 121°C/20-min autoclaved BCG and E. coli were incubated in 20 μM PI solution at room temperature for 1 hour and then washed three times with PBS. Bacteria were fixed in 10% formalin solution for 30 min before inspected under a microscope.

Bacteria analysis using flow cytometry and microscope
Flow cytometry analysis was done with instrumentation and assistance provided by the Stanford Shared FACS Facility. Bacteria were analyzed using a FACSscan with a four-laser, 12-color DsP12 Cytek upgrade (Becton Dickinson, Cytek Biosciences) and evaluated according to their granularity [side scatter (SSC)] property on a log scale, excited by 488 nm later, and filtered with 560-nm short-pass filter and 525/50-nm band-pass filter. Flow cytometry data analysis was done using FlowJo v10 software. The MFI was collected and plotted against the natural autofluorescence of bacteria.

All bacteria images were taken either with a Zeiss AxioImager M1 upright widefield fluorescence/DIC microscope or with a Zeiss LSM710 inverted confocal microscope. Images were processed and converted by ImageJ.

Inhibition study with M. smegmatis
Freshly cultured M. smegmatis (100 μl) was pretreated with PBS, clavulanic acid (2 mg/ml), 50 μM DNB1, or clavulanic acid + DNB1 at 37°C for 2 hours and then incubated with PBS or 10 μM CDG-DNB2 in a final volume of 200 μl at room temperature for 3 hours. Cells were washed with PBS twice before analysis by flow cytometry. M. smegmatis treated with CDG-DNB2 exhibited averagely 90-fold increase of MFI over PBS, which was arbitrarily set to 1 to normalize the other samples with inhibitors. Inhibition study with TG-DNB2 by DNB1 was done under similar conditions.

Inhibition study with BlaC KO H37Rv
Two milliliters of freshly cultured WT, BlaC KO, and vector control H37Rv at OD600 = 1 was pelleted and pretreated with 50 μM DNB1 at 37°C in a 200-μl volume for 1 hour. Two hundred microliters of (20 μM) CDG-DNB2 was added into each tube to reach a 10 μM final concentration and then incubated at room temperature for 2 hours. Mycobacteria were washed three times with PBS, fixed in 10% formalin for 30 min, and then analyzed by flow cytometry. PBS-treated WT, BlaC KO, BlaC compensated, and vector control H37Rv were also analyzed to show the fold increase of fluorescence signal by CDG-DNB2. The fold increase of fluorescence in WT H37Rv by CDG-DNB2 over PBS was arbitrarily set to 1 to normalize the other groups.

Western blot analysis
The procedures for Western blot have been previously described (43). In brief, E. coli TOP10 strains expressing TEM-1 β-lactamase (TEM-1) or BlaC were lysed with a bead beater in PBS containing proteinase inhibitors. Twenty-five micrograms of lysates was loaded on NuPAGE gel for electrophoresis at 200 V for 90 min. Wet transfer was performed using the Bio-Rad transfer kit at 300 mA for 90 min. The transferred nitrocellulose membrane was blocked in PBS containing 5% bovine serum albumin and 0.1% Tween 20 for 1 hour. Primary antibody (His-probe monoclonal IgG, Invitrogen) incubation (1:2000) was performed in the blocking buffer overnight at 4°C. The membrane was then washed four times with PBS containing 0.1% Tween 20. Secondary antibody incubation (LI-COR donkey anti-mouse IgG IRDye 680 or anti-rabbit IgG IRDye 800CW, 1:10,000) was performed in the blocking buffer for 2 hours at room temperature. After washing four times with PBS containing 0.1% Tween 20, the membrane was analyzed using a LI-COR Odyssey imaging system.

Visualization of BCG in macrophage by CDG-DNB3
Mouse RAW 264.7 macrophages were grown on sterile coverslips in a six-well plate in Dulbecco’s modified Eagle’s medium (DMEM) containing 10% fetal bovine serum at 5% CO2 and 37°C to 70 to 80% confluence. Freshly cultured BCG were treated with 10 μM CDG-DNB3 at room temperature for 1 hour and then resuspended in serum-free DMEM to infect macrophages (two to three bacteria per macrophage). After 4 hours of infection, macrophages were washed to remove free bacteria and then incubated with CellMask Deep Red Cell Plasma staining reagent in 1× dilution at 37°C for 10 min. Cells were washed and fixed in 10% formalin. Cells were permeabilized, then incubated with 300 nM DAPI solution for 5 to 10 min, and washed immediately before mounting for imaging. Images of infected macrophages were obtained by confocal microscopy (Zeiss LSM710 inverted confocal microscope) using a 63×/oil immersion objective. The bright-field image was from a single image capture. All fluorescence images were gathered sequentially and stacked. Essential sequential z sections of stained cells were recorded for generation of stacked images through cells. Multichannel three-dimensional projections of fluorescent images were constructed from sequential z sections of cells assembled in ImageJ. All collected fluorescence images were deconvoluted by ImageJ [W. Rasband, National Institutes of Health (NIH)]. Percentage colocalization of material was calculated using the colocalization function in ImageJ.

Staining of processed sputum by CDG-DNB2 and CDG-DNB3
Sputum specimens were processed with NaOH/N-acetyl-L-cysteine, neutralized, and stored in PBS at 4°C for 2 days before incubation in 10 μM CDG-DNB2/PBS solution at room temperature for 1 hour. Sediments were obtained by centrifugation at 4000g for 5 min before washing three times with PBS. Stained samples were fixed in 10% formalin for 30 min, washed once by PBS with last resuspension in citrate buffer (pH 3), and imaged with a Zeiss LSM710 inverted confocal microscope.

For CDG-DNB3, patients’ sputum specimens were collected freshly by the National Tuberculosis Clinical Laboratory at Beijing, China. Specimens were processed with NaOH/N-acetyl-L-cysteine, neutralized, and then incubated in 10 μM CDG-DNB3/PBS solution at room temperature for 1 hour. Sediments were obtained by centrifugation at 4000g for 5 min, then washed three times with PBS before resuspension in citrate buffer (pH 3), and imaged with a Nikon fluorescence microscope.

Microfluidic device design and fabrication
The design and fabrication of the capillary pump–driven bacteria-counting microfluidic device were performed using photoresist molds.
and standard soft lithography methods. The device layout was designed using a CAD drawing program, and the final design was printed on high-resolution transparency sheets, which were used as photolithography masks during the fabrication of the poly(dimethylsiloxane) (PDMS; Dow Corning Sylgard 184) microfluidic chips with the features shown in fig. S24. The device has a sample loading area (a), a fluid flow delaying region (b), an observation chamber with four separate channels (c), and a capillary pump (d) that drives the fluid flow. The channel is 100 μm wide and 100 μm high in the flow-delaying region (b), and each channel is 30 μm wide and 100 μm high in the observation chamber (c). Briefly, a clean and dry silicon wafer (100 mm in diameter and 500 μm in thickness) was treated with hexamethyldisilazane (Sigma-Aldrich) vapor for 2 min in a clean room environment. Subsequently, the wafer was spin–coated with photoresist (Shipley SIR 5740) at 2000 rpm (ramping time, 15 s; spin time, 60 s). The wafer was then soft-baked in an oven at 90°C for 60 min. The transparency mask from above was used for the photolithography. The wafer was then exposed to UV light and developed in 20% Microposist Developer 2401 for 1.5 min to form the final molds for elastomeric chip fabrication. The microfluidic devices were prepared via negative casting on the molds using PDMS. Sylgard 184 A and B components were mixed at a ratio of 20:1 (w/w), degassed in a vacuum chamber, and spin-coated onto the photoresist molds at 5000 rpm. The curing was carried out in an 80°C oven for 1 to 3 hours, and at the end of the curing period, the fabricated devices were peeled off from the molds gently and bonded to microscope slides immediately by conformal contact pressure, followed by an additional baking at 100°C from 2 hours to overnight.

Optical setup, image capturing, and bacteria counting by image analysis
The bacteria-counting device on a standard glass microscope slide was mounted on an inverted microscope with a 63× objective (Olympus America Inc.) for observation under fluorescence illumination. The chip was then loaded with the BCG/PBS to be analyzed using the capillary pumping action of the microfluidic device. The fluorescence pictures of the stained bacteria were captured at rates of 33 frames/s by a digital video camera mounted on the microscope (ORCA-Flash4.0, Hamamatsu) and attached to a computer. In total, 80 frames were captured in 2.42 s. It took 11 frames (1/3 second) for a bacterium to pass through the imaging window (with a length of 210 μm). Movie S4 contains a four times slower version of the captured video defined in green.

For counting the fluorescently stained bacteria, images were collected in grayscale, analyzed, and processed by ImageJ. Every image was subtracted from its next frame to remove the background noise. The generated hyperstack was median-filtered with 2-pixel dimensions to further remove the noise before the sum image of the stack was subtracted from each frame to highlight moving objects in the image. Then, the final frames were automatically analyzed by a custom plugin filter [Broadly Applicable Routines (BAR) for ImageJ] to find the peaks in the gray intensity profile plot values. A baseline threshold for each image stack was manually set to obtain the peak counts corresponding to bacterial counts for each frame, and this was tallied to a total count across the entire loaded sample volume processed.

Statistical analysis
GraphPad Prism 5 was used for plotting and statistical analysis. Significant difference was determined by performing one-way (Fig. 3D and fig. S13C) or two-way (fig. S17) analysis of variance (ANOVA), followed by post hoc Bonferroni’s multiple comparison test to determine the statistical significance with 95% confidence intervals, with *P < 0.05, **P < 0.01, and ***P < 0.001. All error bars in the figures represent ±SD (n = 3). Individual subject-level data are reported in table S2.

**SUPPLEMENTARY MATERIALS**

www.sciencetranslationalmedicine.org/cgi/content/full/10/454/eaar4470/DC1

Materials and Methods
Fig. S1. Synthesis of FI-DNB1, FI-DNB2, and Fl-MNB.
Fig. S2. Synthesis of Rd-DNB and Rd-MNB.
Fig. S3. Synthesis of TG-DNB1.
Fig. S4. Synthesis of TG-DNB2.
Fig. S5. Synthesis of CDG-DNB1.
Fig. S6. Synthesis of CDG-DNB2.
Fig. S7. Synthesis of CDG-DNB3.
Fig. S8. SDS-PAGE analysis of purified M. smegmatis DprE1.
Fig. S9. DprE1 DNA sequence alignment.
Fig. S10. Microscopic imaging and flow cytometry analysis of bacteria labeled by TG and TG-DNB analogs.
Fig. S11. Characterization of TG-DNB2 in M. smegmatis.
Fig. S12. Growth curve of M. smegmatis and BCG.
Fig. S13. Inhibition study of TG-DNB2 with DNB1.
Fig. S14. Characterization of CDG-1 and CDG-DNB analogs in bacteria.
Fig. S15. Western blots detecting the expression of TEM-1 Bla and BlaC in transformed E. coli.
Fig. S16. Labeling of BCG and H37Rv by CDG-DNB2.
Fig. S17. Inhibition study with Blac KO, Blac compensated, and control vector transformed H37Rv and DNB1.
Fig. S18. Labeling of Mtb in processed spumut by CDG-DNB2.
Fig. S19. Evaluation of selectivity of CDG-DNB2/3 for Blac.
Fig. S20. Fluorescence intensity of CDG-DNB3 and TG-DNB2 with or without clavulanic acid, DNB1, or DprE1.
Fig. S21. Characterization of CDG-DNB3 in M. smegmatis, BCG, and TEM-1 Bla or Blac transformed E. coli.
Fig. S22. Specific labeling of viable BCG by CDG-DNB3.
Fig. S23. Labeling of Mtb in processed spumut by CDG-DNB3.
Fig. S24. Overall layout and the functional regions of the microfluidic bacteria-counting device.

Table S1. List of NTMs stained with CDG-DNB3.

Table S2. List of individual subject-level data shown on bar graphs in all figures.

Movie S1. Real-time fluorescence imaging of CDG-DNB2–treated BCG aggregates.
Movie S2. Real-time bright-field imaging of CDG-DNB2–treated BCG aggregates in movies S1.
Movie S3. Infection of macrophages by CDG-DNB3–labeled individual BGC bacilli.

**REFERENCES AND NOTES**

2. Highly blaC-specific for rapid
5. Antimycobacterial activity against clinical strains of M. tuberculosis with different expression of the beta-lactamase gene blac.
7. tubercle drug target.
8. Whole-cell observation of the response to the probe in vivo.
9. The study was supported by a grant from the Swiss National Science Foundation (31003A-162033) to T.D. and H.R. and by the Swiss National Science Foundation (310030_162216) to Y.C.
10. The authors thank K. Johnsson (École Polytechnique Fédérale de Lausanne, Switzerland) for providing the mutant strain of M. tuberculosis with a deletion of the blac gene.
11. The authors declare no competing financial interests.
12. The authors declare no competing financial interests.
13. The authors declare no competing financial interests.
14. The authors declare no competing financial interests.
15. The authors declare no competing financial interests.
16. The authors declare no competing financial interests.
17. The authors declare no competing financial interests.
18. The authors declare no competing financial interests.
19. The authors declare no competing financial interests.
20. The authors declare no competing financial interests.
21. The authors declare no competing financial interests.
22. The authors declare no competing financial interests.
23. The authors declare no competing financial interests.
24. The authors declare no competing financial interests.
25. The authors declare no competing financial interests.
26. The authors declare no competing financial interests.
27. The authors declare no competing financial interests.
28. The authors declare no competing financial interests.
29. The authors declare no competing financial interests.
30. The authors declare no competing financial interests.
31. The authors declare no competing financial interests.
32. The authors declare no competing financial interests.
33. The authors declare no competing financial interests.
34. The authors declare no competing financial interests.
35. The authors declare no competing financial interests.
36. The authors declare no competing financial interests.
37. The authors declare no competing financial interests.
38. The authors declare no competing financial interests.
39. The authors declare no competing financial interests.
40. The authors declare no competing financial interests.
41. The authors declare no competing financial interests.
42. The authors declare no competing financial interests.
43. The authors declare no competing financial interests.
44. The authors declare no competing financial interests.
45. The authors declare no competing financial interests.
46. The authors declare no competing financial interests.
47. The authors declare no competing financial interests.
48. The authors declare no competing financial interests.
49. The authors declare no competing financial interests.
50. The authors declare no competing financial interests.
51. The authors declare no competing financial interests.
52. The authors declare no competing financial interests.
53. The authors declare no competing financial interests.
54. The authors declare no competing financial interests.
55. The authors declare no competing financial interests.
56. The authors declare no competing financial interests.
57. The authors declare no competing financial interests.
58. The authors declare no competing financial interests.
59. The authors declare no competing financial interests.
60. The authors declare no competing financial interests.
61. The authors declare no competing financial interests.
62. The authors declare no competing financial interests.
63. The authors declare no competing financial interests.
64. The authors declare no competing financial interests.
65. The authors declare no competing financial interests.
66. The authors declare no competing financial interests.
67. The authors declare no competing financial interests.
68. The authors declare no competing financial interests.
69. The authors declare no competing financial interests.
70. The authors declare no competing financial interests.
71. The authors declare no competing financial interests.
72. The authors declare no competing financial interests.
73. The authors declare no competing financial interests.
74. The authors declare no competing financial interests.
75. The authors declare no competing financial interests.
76. The authors declare no competing financial interests.
77. The authors declare no competing financial interests.
78. The authors declare no competing financial interests.
79. The authors declare no competing financial interests.
80. The authors declare no competing financial interests.
81. The authors declare no competing financial interests.
82. The authors declare no competing financial interests.
83. The authors declare no competing financial interests.
84. The authors declare no competing financial interests.
85. The authors declare no competing financial interests.
86. The authors declare no competing financial interests.
87. The authors declare no competing financial interests.
88. The authors declare no competing financial interests.
89. The authors declare no competing financial interests.
90. The authors declare no competing financial interests.
91. The authors declare no competing financial interests.
92. The authors declare no competing financial interests.
93. The authors declare no competing financial interests.
94. The authors declare no competing financial interests.
95. The authors declare no competing financial interests.
96. The authors declare no competing financial interests.
97. The authors declare no competing financial interests.
98. The authors declare no competing financial interests.
99. The authors declare no competing financial interests.
100. The authors declare no competing financial interests.
101. The authors declare no competing financial interests.
102. The authors declare no competing financial interests.
103. The authors declare no competing financial interests.
104. The authors declare no competing financial interests.
105. The authors declare no competing financial interests.
106. The authors declare no competing financial interests.
107. The authors declare no competing financial interests.
108. The authors declare no competing financial interests.
109. The authors declare no competing financial interests.
110. The authors declare no competing financial interests.
111. The authors declare no competing financial interests.
112. The authors declare no competing financial interests.
recruitment and assisted with clinical study in China. J.W. and J.X. cultured NTMs and performed CDG-DNB3 staining. D.A. and J.X. designed and fabricated the microfluidic chip, performed the experiments, and collected the video. D.A. developed the method for bacterial counting. Y.C., J.X., and J.R. analyzed all the data and wrote and edited the manuscript, which was approved by all authors. Competing interests: Y.C., J.X., and J.R. are inventors on U.S. patent application US20170044593A1 submitted by Leland Junior Stanford University that covers “Methods for rapid and specific detection of Mycobacterium tuberculosis with a dual targeting fluorogenic probe.” All other authors declare that they have no competing interests.

Data and materials availability: All data associated with this study are present in the paper or Supplementary Materials. Materials are available and will be provided under the material transfer policies of Stanford University. These requests should be directed to the corresponding author. Requests for the option to license the technology can be addressed to the Stanford University Office of Technology Licensing.

Submitted 9 November 2017
Accepted 26 June 2018
Published 15 August 2018
10.1126/scitranslmed.aar4470

Rapid and specific labeling of single live *Mycobacterium tuberculosis* with a dual-targeting fluorogenic probe

Yunfeng Cheng, Jinghang Xie, Kyung-Hyun Lee, Rajiv L. Gaur, Aiguo Song, Tingting Dai, Hongjun Ren, Jiannan Wu, Zhaogang Sun, Niaz Banaei, Demir Akin and Jianghong Rao

*Sci Transl Med* 10, eaar4470.
DOI: 10.1126/scitranslmed.aar4470

Tracking tuberculosis

Tuberculosis, a bacterial infection of the lungs, continues to plague countries worldwide. Cheng et al. developed an imaging probe specific for *Mycobacterium tuberculosis*. The probe fluoresces upon activation by an enzyme in the bacteria, and fluorescence is retained by modification of a second bacterial enzyme required for formation of the bacterial cell wall. The probe could identify single live tuberculosis bacteria from nontuberculosis bacteria and dead bacteria, and was compatible with patient sputum samples. The authors also developed a microfluidic chip to aid in automating live tuberculosis bacterial counts from sputum samples. This probe and chip platform could aid in drug testing and diagnosis.